Application of polydatin in preparation of medicine for improving and repairing cryptorchis spermatogenic function damage
By using drugs prepared by syringin, the problems of poor efficacy and major side effects of cryptorchidism in the prior art have been solved, and sperm-generating function has been significantly improved, reproductive repair is promoted, and oxidative stress and inflammatory response are alleviated, and new candidate drugs for the treatment of cryptorchidism are provided.
Patent Information
- Application Number
- CN202510501091.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-21
- Publication Date
- 2025-08-08
AI Technical Summary
The drugs used in the prior art for the treatment of cryptorchidism are poor and have great side effects, making it difficult to effectively improve and repair spermatogenetic damage.
Using kazuminoside as the main active ingredient, drugs are prepared to improve and repair cryptorchid spermatogenesis and reduce oxidative stress and inflammatory responses by increasing the weight of mice, increasing the weight of the testicles, improving spermatogenesis, promoting spermatogenesis and regulating the metabolic group in the testicles.
Knotweed significantly improves spermatogenesis, promotes reproductive repair, improves serum testosterone and gonadotropin-releasing hormone levels, enhances spermatogenesis, reduces oxidative stress and inflammatory responses, and has fewer side effects, demonstrating the potential application value in the field of reproductive health.
Smart Images

Figure CN120437146A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of polydatin in the preparation of a drug for improving and repairing cryptorchidism spermatogenesis damage. Background Art
[0002] Male infertility is a major research hotspot. Cryptorchidism is a common congenital malformation caused by the failure of the testicles to fully descend into the scrotum, leading to spermatogenesis dysfunction. This dysfunction is often associated with inflammation triggered by oxidative stress. Currently, treatments for cryptorchidism remain immature.
[0003] Polydatin is a natural compound extracted from the plant Polygonum cuspidatum. It is a glycosylated derivative of resveratrol (RSV). Polydatin exhibits antioxidant and anti-inflammatory properties, scavenging free radicals, reducing cellular damage caused by oxidative stress, and inhibiting the expression of inflammatory factors. These effects help protect cells from oxidative stress and inflammation and may have a positive impact on spermatogenesis disorders.
[0004] Polydatin can affect the human body in multiple ways. In terms of heart protection, Hu Xiaojun et al. found that polydatin can inhibit myocardial fibrosis and cell death by activating Sirt1. At the same time, Li Rui et al. found that polydatin also has a significant protective effect on the liver, reducing non-alcoholic fatty liver inflammation and fibrosis, blocking inflammatory signaling pathways, and alleviating hepatic steatosis and cell apoptosis. In addition, in a Parkinson's disease model, Huang Bingxu et al. found that polydatin can improve behavioral dysfunction, increase the survival rate of dopaminergic neurons, reduce microglial activation, and inhibit inflammatory responses. These effects are closely related to the AKT / GSK3β-Nrf2 signaling axis activated by polydatin, which in turn inhibits the phosphorylation of NF-κB p65 and the release of pro-inflammatory mediators.
[0005] Currently, the Western medicine tadalafil tablets are mostly used to treat spermatogenesis disorders. Its side effects are relatively large and it is more likely to cause some irreversible damage to the users. Summary of the Invention
[0006] In view of the technical problems that current technologies for the treatment of cryptorchidism and drugs for improving and repairing cryptorchidism spermatogenesis damage are poorly effective and have significant side effects, the purpose of the present invention is to provide a method for using polydatin in the preparation of a drug for improving and repairing cryptorchidism spermatogenesis damage. The drug uses polydatin as the main active ingredient and has the effects of increasing mouse body weight, increasing mouse testicular weight, improving spermatogenesis, restoring the reproduction of cryptorchidism mice, promoting spermatogenesis, and regulating the metabolome in the mouse testis.
[0007] The present invention is achieved through the following technical solutions:
[0008] A use of polydatin in the preparation of a drug for improving and repairing cryptorchidism spermatogenesis damage.
[0009] Preferably, the drug is used to increase the body weight of mice, increase the weight of mouse testicles, improve spermatogenesis, repair the reproduction of cryptorchid mice, promote spermatogenesis, and regulate the metabolome in mouse testicles.
[0010] Preferably, the reproductive repair of cryptorchid mice is specifically to arrange spermatogenic cells at all levels in the mouse testicles in an orderly manner and reduce the shedding of spermatogenic cells.
[0011] Preferably, the promotion of spermatogenesis is specifically to increase hormone levels.
[0012] Preferably, the hormone levels are testosterone, folliculin, gonadal hormone-releasing hormone, progesterone, folliculin, estradiol, superoxide dismutase, and malondialdehyde in mouse serum.
[0013] Preferably, the regulating the metabolome in the mouse testis is specifically to reduce oxidative stress and inflammatory response.
[0014] A medicine for improving and repairing cryptorchidism spermatogenesis damage, wherein the main active ingredient of the medicine is polydatin.
[0015] Preferably, the drug further comprises pharmaceutically acceptable excipients.
[0016] Preferably, the pharmaceutically acceptable excipients include any one or more combinations of diluents, excipients, disintegrants, fillers, binders, lubricants, flavoring agents, surfactants, and stabilizers.
[0017] Compared with the prior art, the present invention has at least the following technical effects:
[0018] (1) The present invention provides an application of polydatin in the preparation of a drug for improving and repairing cryptorchidism spermatogenesis damage, wherein the drug contains polydatin as the main active ingredient.
[0019] (2) The present invention provides a solution that experimentally establishes a cryptorchid mouse model and further explores the ameliorative and restorative effects of polydatin on cryptorchid spermatogenesis. The experiments demonstrate that polydatin can effectively improve spermatogenesis and promote reproductive restoration in cryptorchid mice, while also increasing serum testosterone and gonadotropin-releasing hormone levels, hormones that promote spermatogenesis. This restorative effect is dose-dependent, with the optimal restoration effect achieved at a polydatin concentration of 50-100 mg / kg.
[0020] (3) In addition, polydatin can regulate the metabolome in the testis of mice, reduce oxidative stress and inflammatory response, thereby affecting and improving sperm count and epididymal weight.
[0021] (4) Compared with Western medicine, polydatin is more easily absorbed by the human body and has fewer side effects, demonstrating its potential application value in the field of reproductive health.
[0022] (V) In summary, polydatin, as a natural compound with antioxidant and anti-inflammatory properties, showed significant effects in improving spermatogenesis impairment in male mice.
[0023] This study not only provides experimental evidence for the application of polydatin in reproductive health, but also offers a new drug candidate for the treatment of male infertility, such as cryptorchidism. Further research into the mechanism of action of polydatin is expected to lead to new breakthroughs in the treatment of male infertility. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Schematic diagram of the weekly weight measurement results of mice in each group;
[0025] Figure 2 Schematic diagram of the comparison of organ coefficients of mice in each group;
[0026] Figure 3 Schematic diagram of the effect of each group on the sperm count of mice;
[0027] Figure 4 Schematic diagram of HE staining of testicles of mice in each group;
[0028] Figure 5 Schematic diagram of the effects of each group on serum hormone level defects caused by cryptorchidism surgery. DETAILED DESCRIPTION
[0029] The embodiments of the present invention will be described in detail below with reference to the examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. Specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0030] Experimental content:
[0031] 1. Experimental purpose: To observe the improvement and repair effect of polydatin on spermatogenesis damage in mice
[0032] 2. Experimental Materials and Methods
[0033] 2.1 Construction of cryptorchidism mouse model
[0034] Thirty 15-day-old male Kunming mice were anesthetized with ether and fixed in the supine position. The abdominal cavity was disinfected, a small incision was made, and the fur and muscle were dissected layer by layer. After the fat head was identified, the testicle was pulled out of the scrotum, the ligaments were cut, and the testicle was fixed to the abdominal cavity, taking care not to damage the testicle, epididymis, or vas deferens. After the surgery, all layers were sutured, and the mice were placed in an incubator for observation, and their survival was recorded.
[0035] 2.2 Animal grouping and drug administration
[0036] Two weeks after surgery, the azoospermia model was essentially stable. Polydatin was dissolved in saline to prepare solutions of 25 mg / kg, 50 mg / kg, and 100 mg / kg. The mice were gavaged at a dose of 10 μl / g, depending on their body weight. The mice were weighed and recorded weekly, and the drug was administered continuously for 35 days.
[0037] 2.3 HE staining
[0038] Testicular tissue sectioning: Prepare glycerol and a 37°C water bath. Use a microtome to cut the testicular tissue into 5 μm slices. Place the slices in a water bath for approximately three minutes. Apply glycerol protein to a glass slide. Place the testicular slices on the glycerol protein side of the slide (mark it in advance). Finally, bake the slide in an oven at 60°C for 1 hour.
[0039] Xylene dewaxing I for 10 min → Xylene dewaxing II for 10 min → 100% alcohol for 5 min → 95% alcohol for 5 min → 80% alcohol for 5 min → 70% alcohol for 5 min → distilled water immersion → hematoxylin for 20 s → tap water rinse → eosin for 2 s → tap water rinse, observe the sections, take photos and take samples.
[0040] 2.4 Detection of mouse epididymal weight, sperm count, and serum testosterone level
[0041] The left testicle and epididymis of male mice were weighed.
[0042] The epididymal tail was peeled off, 1 mL of normal saline was added to a 1.5 mL centrifuge tube to prepare a sperm suspension, and the suspension was equilibrated in a 37°C incubator for 15 min. 18 μL of the suspension was then dropped into a sperm counting plate to detect the total number of sperm.
[0043] 2.5 Serum ELISA test
[0044] Mouse serum was removed from a -80°C freezer, reconstituted on ice, and serum malondialdehyde (MDA), superoxide dismutase (SOD), estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), gonadotropin-releasing hormone (GnRH), and testosterone (T) levels were measured by ELISA. The results were then analyzed using a microplate reader (n = 450 nm).
[0045] 2.6 Testicular tissue protein detection
[0046] Protein quantification was performed using the BCA method, and the sample concentration and protein loading were calculated based on the standard curve. Proteins were separated by SDS-PAGE gel electrophoresis at a constant voltage of 120V for 90 minutes. The proteins on the gel were transferred to the PVDF membrane using the wet transfer method. When assembling the wet transfer cassette, the sponge, filter paper, gel, PVDF membrane, filter paper, and sponge were placed in a "sandwich" structure, and the membrane was transferred at a constant current of 250mA. After the transfer was completed, the PVDF membrane was washed and incubated with 5% skim milk powder blocking solution at room temperature for 2 hours, incubated with the primary antibody at 4°C overnight, and then incubated with the secondary antibody at room temperature for 1 hour, with multiple washes required during this period. Finally, ECL chemiluminescence development was performed using the ChemiDocTMMP chemiluminescence imaging system. After the system was preheated, the de-liquidated PVDF membrane was placed on the operating plate, and the developer solution was added and incubated in the dark for 3 minutes to complete the development and save the image.
[0047] 2.7 Statistical methods
[0048] The experimental data were statistically analyzed using Graph-Pad Prism software. Samples are represented by n, and P < 0.05 indicates a statistically significant difference, while P > 0.05 indicates no statistically significant difference.
[0049] 3. Experimental Results and Analysis
[0050] 3.1 Analysis of mouse body weight
[0051] like Figure 1 The figure shows the weekly weight measurements of mice in each group. n = 6. BO represents 45-day-old normal mice gavaged with saline; CO represents 45-day-old cryptorchid mice gavaged with saline; P25, P50, and P100 represent 45-day-old cryptorchid mice gavaged with different doses.
[0052] Combining the results Figure 1 The mice were divided into the BO group (normal mice), the CO group (gavage with normal saline), and the P25, P50, and P100 groups (gavage with 25 mg / kg, 50 mg / kg, and 100 mg / kg of polydatin, respectively).
[0053] The body weight of mice in each group increased steadily, but there was no significant difference between the groups. It is speculated that surgery and drugs had no significant effect on body weight.
[0054] 3.2 Analysis of mouse testicles and other organs
[0055] like Figure 2The figure shows the comparison of organ coefficients of mice in each group. The figure shows the coefficients of specific organs, namely brain, cerebellum, left and right testicles, left and right kidneys, liver, lungs, pancreas, colon, heart, spleen, and stomach.
[0056] Combining the results Figure 2 After the mice were dissected, their organs were weighed and stored at -80°C. Polydatin at different doses (25 mg / kg, 50 mg / kg, and 100 mg / kg) had a significant effect on the mouse testes. The right testicle weights of the BO group were significantly different from those of the CO, P25, and P50 groups (P < 0.05), and the left testicle weights were significantly different from those of the CO, P25, and P100 groups (P < 0.05). Cryptorchidism surgery disrupts the spermatogenic environment, leading to decreased testicular weight.
[0057] The testicular weight in the polydatin group was higher than that in the CO group but slightly lower than that in the BO group, indicating that polydatin improves testicular weight and function. The CO group had smaller kidneys, which may be related to cryptorchidism surgery.
[0058] Polydatin had a dose effect on the kidney, but the difference was not significant (P>0.05).
[0059] There were significant differences in spleen between the P100 group and the CO and P25 groups (P>0.05), which may be related to cryptorchidism surgery and requires further exploration.
[0060] There were no significant differences in other organs (P>0.05).
[0061] 3.3 Sperm count
[0062] like Figure 3 The figure shows the effect of each group on the sperm count of mice. In the figure, different uppercase and lowercase letters indicate extremely significant differences (P<0.01), the same uppercase letters with different lowercase letters indicate significant differences (P<0.05), and the same uppercase letters indicate no significant differences (P>0.05).
[0063] Combining the results Figure 3 As can be seen, the sperm count in the normal BO group was significantly higher than in the other groups. Furthermore, the sperm count in the polydatin groups was significantly higher than in the CO group, but slightly lower than in the BO group. This suggests that polydatin improves and protects spermatogenesis in mice to a certain extent. Furthermore, the sperm counts in the polydatin groups varied.
[0064] Table 1 Sperm counts in each group (mean values)
[0065] Group dose Sperm count (100 million / mL) BO - 0.0195 CO - - P25 25 mg / kg 0.00075 P50 50 mg / kg 0.001928571 P100 100mg / kg 0.000714
[0066] 3.4 HE staining of mouse testis
[0067] like Figure 4The following are the schematic diagrams of HE staining of the testes of mice in each group: BO group (A), CO group (B), P25 group (C), P50 group (D), and P100 group (E).
[0068] Combining the results Figure 4 The results show that the spermatogenic epithelium of mice in the BO group was intact, with spermatogenic cells at all levels arranged tightly and orderly from the base of the seminiferous tubules to the lumen. Compared with the BO group, the spermatogenic cells at all levels in the CO group were loosely and disorderly arranged, with basal spermatogenic cells falling off and the number of spermatogenic cell layers decreasing.
[0069] Compared with the CO group, the structure of the spermatogenic epithelium of mice in the P25 group was relatively more complete, and spermatogenic cells at all levels fell off, playing a repairing role at the spermatogenic cell level.
[0070] The repair effect of group P50 was more obvious than that of group P25. The repair effect of group P100 was the most significant, and spermatogenesis was observed.
[0071] In summary, as the concentration of polydatin in the drug-treated group gradually increased, the repair effect on mice became more obvious.
[0072] 3.5 Mouse serum analysis
[0073] ELISA kits were used to detect the levels of testosterone (T), malondialdehyde (MDA), superoxide dismutase (SOD), estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and gonadotropin-releasing hormone (GnRH) in the serum of mice in each group (A).
[0074] like Figure 5 Shown is a schematic diagram of the effects of each group on serum hormone level defects caused by cryptorchidism surgery.
[0075] In the figure, different uppercase and lowercase letters in the columns indicate extremely significant differences (P<0.01), the same uppercase letters but different lowercase letters indicate significant differences (P<0.05), and the same lowercase letters indicate no significant differences (P>0.05).
[0076] Studies have shown that testosterone (T) is positively correlated with spermatogenesis in male mice, that is, the higher the testosterone level, the more active the spermatogenesis in mice.
[0077] This experiment found that the testosterone concentration of mice in the P100 group was higher than that in the other groups, with a significant difference and statistical significance (P<0.05).
[0078] Figure 5The results showed that polydatin can increase the testosterone level of cryptorchid mice and promote spermatogenesis, but the testosterone level of mice in the polydatin P100 group was higher. There was a dose effect of polydatin and an optimal concentration. Gonadotropin-releasing hormone (GnRH) is beneficial to spermatogenesis and promotes testosterone secretion. P50 was statistically significant compared with P100 (P<0.05). The luteinizing hormone (LH) in the BO group was statistically significant compared with P100, P<0.05, and the luteinizing hormone (LH) in the BO group was statistically significant compared with P25, P<0.05. Although the hormones of follicle-stimulating hormone (FSH), estradiol (Estradiol), superoxide dismutase (SOD), and malondialdehyde (MDA) in the CO group were different from those in the other groups, no significant characteristics were found (P>0.05).
[0079] Combining the results Figure 5 It is known that cryptorchidism surgery can disrupt the reproductive environment of mice, disrupt the spermatogenesis process, and change the hormone levels related to mouse reproduction. Polydatin can significantly improve the hormone level changes caused by cryptorchidism surgery and promote spermatogenesis in mice.
[0080] However, experiments have found that polydatin has a dose effect and 50-100 mg / kg may be the optimal concentration for promoting spermatogenesis.
[0081] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.
Claims
1. The application of polydatin in the preparation of drugs to improve and repair cryptorchidism spermatogenesis damage.
2. An application according to claim 1, characterized in that: The drug is used in increasing the body weight of mice, increasing the weight of mouse testicles, improving spermatogenesis, repairing the reproduction of cryptorchidistic mice, promoting spermatogenesis, and regulating the metabolome in mouse testicles.
3. An application according to claim 2, characterized in that: The reproductive repair of cryptorchid mice specifically includes neat arrangement of spermatogenic cells at all levels in the mouse testicles and reduction of spermatogenic cell shedding.
4. The application according to claim 2, characterized in that: The promoting spermatogenesis specifically refers to increasing hormone levels.
5. The application according to claim 4, characterized in that: The hormone levels are testosterone, folliculin, gonadal hormone-releasing hormone, progesterone, folliculin, estradiol, superoxide dismutase, and malondialdehyde in mouse serum.
6. The application according to claim 2, characterized in that: The regulation of the metabolome in the mouse testis specifically reduces oxidative stress response and inflammatory response.
7. A drug for improving and repairing cryptorchidism spermatogenesis damage, characterized in that: The main active ingredient of the medicine is polydatin as claimed in claim 1.
8. The drug for improving and repairing cryptorchidism spermatogenesis damage according to claim 7, characterized in that: The drug also includes pharmaceutically acceptable excipients.
9. The drug for improving and repairing cryptorchidism spermatogenesis damage according to claim 8, characterized in that: The pharmaceutically acceptable excipients include any one or more combinations of diluents, excipients, disintegrants, fillers, binders, lubricants, flavoring agents, surfactants, and stabilizers.
